The possible separation of 12-O-tetradecanoylphorbol-13-acetate-induced skin inflammation and hyperplasia by compound A

Molecular Carcinogenesis

Volumn 52, Issue 6, 2013, Pages 488-496

  Kowalczyk, Piotr ^a   Kowalczyk, Magdalena C ^a   Junco, Jacob J ^a   Tolstykh, Olga ^a   Kinjo, Tatsuya ^a   Truong, Ha ^a   Walaszek, Zbigniew ^a   Hanausek, Margaret ^a   Slaga, Thomas J ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Dissociated glucocorticoids; Glucocorticoid receptor; SENCAR mice

Indexed keywords

CYCLOOXYGENASE 2; FLUOCINOLONE ACETONIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN C JUN; PROTEIN P50; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CELL PROLIFERATION; CONTROLLED STUDY; DERMATITIS; EPIDERMIS HYPERPLASIA; FEMALE; KERATINOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ACETATES; ANIMALS; CYCLOOXYGENASE 2; CYTOKINES; DRUG ERUPTIONS; EPIDERMIS; FEMALE; HYPERPLASIA; MICE; MICE, INBRED SENCAR; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-JUN; RECEPTORS, GLUCOCORTICOID; RNA, MESSENGER; SKIN; TETRADECANOYLPHORBOL ACETATE; TRANSCRIPTIONAL ACTIVATION; TYRAMINE;

MUS;

EID: 84876448385     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.21883     Document Type: Article

References (42)

1. Slaga TJ. Can tumour promotion be effectively inhibited? IARC Sci Publ 1984; 56: 497- 506.
2. Ray A, Prefontaine KE. Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc Natl Acad Sci USA 1994; 91: 752- 756.
3. Yang-Yen HF, Chambard JC, Sun YL, et al. Transcriptional interference between c-Jun and the glucocorticoid receptor: Mutual inhibition of DNA binding due to direct protein-protein interaction. Cell 1990; 62: 1205- 1215.
4. Tuckermann JP, Reichardt HM, Arribas R, Richter KH, Schutz G, Angel P. The DNA binding-independent function of the glucocorticoid receptor mediates repression of AP-1-dependent genes in skin. J Cell Biol 1999; 147: 1365- 1370.
5. Schwarz JA, Viaje A, Slaga TJ. Fluocinolone acetonide: A potent inhibitor of mouse skin tumor promotion and epidermal DNA synthesis. Chem Biol Interact 1977; 17: 331- 347.
6. Strawhecker JM, Pelling JC. Inhibition of mouse skin tumorigenesis by dexamethasone occurs through a Ha-ras-independent mechanism. Carcinogenesis 1992; 13: 2075- 2080.
7. Budunova IV, Carbajal S, Kang H, Viaje A, Slaga TJ. Altered glucocorticoid receptor expression and function during mouse skin carcinogenesis. Mol Carcinog 1997; 18: 177- 185.
8. Cheng Y, Li J, Martinka M, Li G. The expression of NAD(P)H:quinone oxidoreductase 1 is increased along with NF-kappaB p105/p50 in human cutaneous melanomas. Oncol Rep 2010; 23: 973- 979.
9. Cooper SJ, Bowden GT. Ultraviolet B regulation of transcription factor families: Roles of nuclear factor-kappa B (NF-kappaB) and activator protein-1 (AP-1) in UVB-induced skin carcinogenesis. Curr Cancer Drug Targets 2007; 7: 325- 334.
10. Dong Z, Birrer MJ, Watts RG, Matrisian LM, Colburn NH. Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells. Proc Natl Acad Sci USA 1994; 91: 609- 613.
11. Schacke H, Schottelius A, Docke WD, et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci USA 2004; 101: 227- 232.
12. Hayashi R, Wada H, Ito K, Adcock IM. Effects of glucocorticoids on gene transcription. Eur J Pharmacol 2004; 500: 51- 62.
13. Vayssiere BM, Dupont S, Choquart A, et al. Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Mol Endocrinol 1997; 11: 1245- 1255.
14. Belvisi MG, Wicks SL, Battram CH, et al. Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of transrepression from transactivation activity. J Immunol 2001; 166: 1975- 1982.
15. Belvisi MG, Brown TJ, Wicks S, Foster ML. New glucocorticosteroids with an improved therapeutic ratio? Pulm Pharmacol Ther 2001; 14: 221- 227.
16. Rosen J, Miner JN. The search for safer glucocorticoid receptor ligands. Endocr Rev 2005; 26: 452- 464.
17. Schacke H, Hennekes H, Schottelius A, et al. SEGRAs: A novel class of anti-inflammatory compounds. Ernst Schering Res Found Workshop 2002; 40: 357- 371.
18. Miner JN, Ardecky B, Benbatoul K, et al. Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile. Proc Natl Acad Sci USA 2007; 104: 19244- 19249.
19. Friedman ZY. Recent advances in understanding the molecular mechanisms of tamoxifen action. Cancer Invest 1998; 16: 391- 396.
20. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998; 339: 1609- 1618.
21. Schroder FH. Antiandrogens as monotherapy for prostate cancer. Eur Urol 1998; 34: 12- 17.
22. Wajsman Z. Arguments for the long-term use of combined androgen blockade. Eur Urol 1998; 34: 25- 28.
23. 3, 4-fquinolin-3-ones as a novel class of nonsteroidal progesterone receptor agonists: Effect of A-ring modification. J Med Chem 1999; 42: 1466- 1472.
24. Zhi L, Tegley CM, Pio B, et al. Nonsteroidal progesterone receptor antagonists based on 6-thiophenehydroquinolines. Bioorg Med Chem Lett 2000; 10: 415- 418.
25. Louw A, Swart P, de Kock SS, van der Merwe KJ. Mechanism for the stabilization in vivo of the aziridine precursor -(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride by serum proteins. Biochem Pharmacol 1997; 53: 189- 197.
26. De Bosscher K, Vanden Berghe W, Beck IM, et al. A fully dissociated compound of plant origin for inflammatory gene repression. Proc Natl Acad Sci USA 2005; 102: 15827- 15832.
27. Yemelyanov A, Czwornog J, Chebotaev D, et al. Tumor suppressor activity of glucocorticoid receptor in the prostate. Oncogene 2007; 26: 1885- 1896.
28. Yemelyanov A, Czwornog J, Gera L, Joshi S, Chatterton RT, Jr., Budunova I. Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells. Cancer Res 2008; 68: 4763- 4773.
29. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: How are they linked? Free Radic Biol Med 2010; 49: 1603- 1616.
30. Piechaczyk M, Farras R. Regulation and function of JunB in cell proliferation. Biochem Soc Trans 2008; 36: 864- 867.
31. Park SA, Kim EH, Na HK, Surh YJ. KG-135 inhibits COX-2 expression by blocking the activation of JNK and AP-1 in phorbol ester-stimulated human breast epithelial cells. Ann N Y Acad Sci 2007; 1095: 545- 553.
32. Seibert K, Masferrer JL. Role of inducible cyclooxygenase (COX-2) in inflammation. Receptor 1994; 4: 17- 23.
33. Kim SO, Kundu JK, Shin YK, et al. [6]-Gingerol inhibits COX-2 expression by blocking the activation of p38 MAP kinase and NF-kappaB in phorbol ester-stimulated mouse skin. Oncogene 2005; 24: 2558- 2567.
34. He G, Karin M. NF-kappaB and STAT3-Key players in liver inflammation and cancer. Cell Res 2011; 21: 159- 168.
35. Kelly EJ, Sandgren EP, Brinster RL, Palmiter RD. A pair of adjacent glucocorticoid response elements regulate expression of two mouse metallothionein genes. Proc Natl Acad Sci USA 1997; 94: 10045- 10050.
36. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006; 54: 1- 15; quiz 16-18.
37. Schoepe S, Schacke H, May E, Asadullah K. Glucocorticoid therapy-induced skin atrophy. Exp Dermatol 2006; 15: 406- 420.
38. Li J, Johnson TA, Hanson LA, Beer DG. Loss of glucocorticoid-dependent growth inhibition in transformed mouse lung cells. Mol Carcinog 1996; 16: 213- 220.
39. Moalli PA, Rosen ST. Glucocorticoid receptors and resistance to glucocorticoids in hematologic malignancies. Leuk Lymphoma 1994; 15: 363- 374.
40. Dewint P, Gossye V, De Bosscher K, et al. A plant-derived ligand favoring monomeric glucocorticoid receptor conformation with impaired transactivation potential attenuates collagen-induced arthritis. J Immunol 2008; 180: 2608- 2615.
41. Gossye V, Elewaut D, Van Beneden K, Dewint P, Haegeman G, De Bosscher K. A plant-derived glucocorticoid receptor modulator attenuates inflammation without provoking ligand-induced resistance. Ann Rheum Dis 2009; 29: 291- 296.
42. Zhang Z, Zhang ZY, Schluesener HJ. Compound A, a plant origin ligand of glucocorticoid receptors, increases regulatory T cells and M2 macrophages to attenuate experimental autoimmune neuritis with reduced side effects. J Immunol 2009; 183: 3081- 3091.